Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
ALDOB K87 Lactylation Drives Mitochondrial Fission in PH
2026-06-25
The reference study reveals that ALDOB K87 lactylation is a pivotal driver of mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). These findings establish a mechanistic link between lactate metabolism, mitochondrial dynamics, and smooth muscle cell proliferation, offering new avenues for translational vascular research.
-
ATRX-Deficient Glioma Cells: Enhanced Sensitivity to RTK Inh
2026-06-25
Pladevall-Morera et al. demonstrate that high-grade glioma cells lacking ATRX are especially sensitive to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. This discovery suggests ATRX status is a key factor in optimizing targeted therapy strategies and interpreting clinical trial data in glioma research.
-
Resveratrol and SIRT1: Translating Mitochondrial Biogenesis
2026-06-24
This thought-leadership article dissects the mechanistic and translational significance of resveratrol as a SIRT1 activator, focusing on neurodegenerative paradigms. It synthesizes the latest evidence on mitochondrial biogenesis, apoptosis inhibition, and experimental optimization, while providing practical protocol guidance for translational researchers. The discussion anchors to peer-reviewed findings, highlights APExBIO's product standards, and frames a strategic future for SIRT1-driven interventions.
-
Dihydroethidium in Oxidative Stress Assays: Advanced Workflo
2026-06-23
Dihydroethidium (DHE) stands out as a gold-standard probe for live-cell superoxide detection, empowering researchers to quantify oxidative stress with high specificity and sensitivity. This guide distills state-of-the-art experimental strategies, troubleshooting insights, and cross-disease applications, drawing from cutting-edge lung cancer research and practical lab experience.
-
Targeted SPP1 Inhibition in Tumor Macrophages Reduces Tumor
2026-06-23
Kartal et al. report a phenotypic screening strategy to identify small molecule inhibitors capable of suppressing SPP1 expression in tumor-associated macrophages (TAM), culminating in a nanoformulation (CANDI460) that leads to significant tumor regression in murine models. These findings provide a new direction for TAM-targeted therapies, highlighting the importance of SPP1 as a functional target rather than just a biomarker.
-
Ibuprofen in Cancer Research: Beyond COX Inhibition to Apopt
2026-06-22
Explore the multifaceted role of Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) in cancer research, from cyclooxygenase inhibition to apoptosis induction in colon carcinoma cells. This article delivers a unique, mechanism-oriented perspective on Ibuprofen’s advanced applications and practical assay guidance.
-
Pazopanib Hydrochloride in Cancer Research: Applied Workflow
2026-06-22
Pazopanib Hydrochloride (GW786034) empowers translational oncology through precise inhibition of multiple receptor tyrosine kinases, making it a cornerstone for anti-angiogenic and cytotoxicity studies. This article offers advanced protocol guidance, troubleshooting, and workflow optimization rooted in recent in vitro innovations and systems pharmacology.
-
Chenodeoxycholic Acid in Renal and Metabolic Research Workfl
2026-06-21
Chenodeoxycholic Acid (CDCA) is redefining nuclear receptor signaling and renal protection, empowering researchers to model and modulate the FXR-KLF11 axis in acute kidney injury and cholesterol metabolism. This article details protocol enhancements, troubleshooting insights, and translational applications for maximizing data quality using APExBIO’s high-quality CDCA.
-
Leucomycin (Kitasamycin): Precision in Translational Inhibit
2026-06-20
Explore the unique properties and advanced assay applications of Leucomycin (kitasamycin), a potent macrolide antibiotic. Discover new insights into impurity analysis and practical guidance for translational inhibition studies.
-
Murine RNase Inhibitor: Oxidation-Resistant RNA Protection
2026-06-19
Murine RNase Inhibitor (K1046) is a recombinant mouse protein that provides robust, oxidation-resistant RNA degradation prevention in molecular biology workflows. Its specificity for pancreatic-type RNases and stability under low reducing conditions make it a preferred RNase A inhibitor for sensitive applications like real-time RT-PCR and cDNA synthesis.
-
2'3'-cGAMP (sodium salt): Unmasking Tumor Immune Evasion
2026-06-19
Explore how 2'3'-cGAMP (sodium salt) enables advanced dissection of tumor-driven immune evasion via the cGAS-STING pathway. This article reveals practical and mechanistic insights for immunology and cancer research, grounded in the latest exosomal ENPP1 discoveries.
-
Cabozantinib XL184: Optimizing Kinase Inhibition in RCC Mode
2026-06-18
Harness Cabozantinib’s multi-kinase targeting to dissect timescale-dependent signaling and cell motility adaptation in renal cell carcinoma. Implement robust, phosphoproteomics-ready workflows and troubleshoot resistance with insights from the latest systems-level studies.
-
Strategic Lysosome Tracking: Translational Power of Lyso-Tra
2026-06-18
This thought-leadership article explores the frontier of live-cell lysosome imaging, spotlighting Lyso-Tracker Red’s pivotal role in decoding disease-relevant lysosomal dynamics. It weaves mechanistic insights from recent advances in cancer immunotherapy with actionable, protocol-driven guidance for translational researchers, while positioning APExBIO’s probe as an indispensable tool for next-generation biomedical discovery.
-
Pazopanib (GW-786034) in Cancer Research: Workflow and Insig
2026-06-17
Pazopanib (GW-786034) empowers oncology researchers with robust, selective inhibition of key angiogenic and proliferative pathways, enabling advanced studies on tumor growth suppression and therapeutic synergy. Recent findings in ATRX-deficient glioma models reveal new dimensions for precision targeting, while optimized protocols from APExBIO ensure reproducible, high-impact experimental outcomes.
-
Transmission Dynamics of Carbapenemase Genes in CREC in Chin
2026-06-17
This study systematically characterizes the prevalence and transmission mechanisms of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong Province during 2022–2024. The findings reveal a high frequency of multidrug resistance and efficient gene transfer, highlighting critical challenges for infection control and antibiotic stewardship.